**CARE Checklist (2016) of information to include when writing a case report**

|  |  |  |  |
| --- | --- | --- | --- |
| **Topic** | **Item** | **Checklist item description** | **Line / Page** |
| **Title** | **1** | The words “case report” should be in the title along with what is of greatest interest in this case | 2 /1 |
| **Key Words** | **2** | The key elements of this case in 2 to 5 key words | 19-20 /3 |
| **Abstract** | **3a** | Introduction—What is unique about this case? What does it add to the medical literature? | 21-23 / 3 |
|  | **3b** | The main symptoms of the patient and the important clinical findings | 7-10 / 3 |
|  | **3c** | The main diagnoses, therapeutics interventions, and outcomes | 6-8 / 3 |
|  | **3d** | Conclusion—What are the main “take-away” lessons from this case? | 14-18 /3 |
| **Introduction** | **4** | Brief background summary of this case referencing the relevant medical literature | 1-29 / 4 |
| **Patient Information** | **5a** | Demographic information (such as age, gender, ethnicity, occupation) | 10-12/ 5 |
|  | **5b** | Main symptoms of the patient (his or her chief complaints) | 13-15 / 5 |
|  | **5c** | Medical, family, and psychosocial history including co-morbidities, and relevant genetic information | 14-15 / 5 |
|  | **5d** | Relevant past interventions and their outcomes | 15-16/5 |
| **Clinical Findings** | **6** | Describe the relevant physical examination (PE) findings | 15 / 5 |
| **Timeline** | **7** | Depict important milestones related to your diagnoses and interventions (table or figure) | 1-15/12 |
| **Diagnostic Assessment** | **8a** | Diagnostic methods (such as PE, laboratory testing, imaging, questionnaires) | 15-18 / 52-3 / 12 |
|  | **8b** | Diagnostic challenges (such as financial, language, or cultural) | 16-21/5 |
|  | **8c** | Diagnostic reasoning including other diagnoses considered | 13-14 / 5 |
|  | **8d** | Prognostic characteristics (such as staging in oncology) where applicable |  |
| **Therapeutic Intervention** | **9a** | Types of intervention (such as pharmacologic, surgical, preventive, self-care) | 22-27 / 5 |
|  | **9b** | Administration of intervention (such as dosage, strength, duration) | 26-27 / 5 |
|  | **9c** | Changes in intervention (with rationale) | 22-29 / 52-21 / 65-15 / 12 |
| **Follow-up and Outcomes** | **10a** | Clinician-assessed outcomes and when appropriate patient-assessed outcomes | 1-8 / 7 |
|  | **10b** | Important follow-up test results | 1-15 / 717-23 / 12 |
|  | **10c** | Intervention adherence and tolerability (How was this assessed?) | 23-24 /6 |
|  | **10d** | Adverse and unanticipated events |  |
| **Discussion** | **11a** | Discussion of the strengths and limitations in the management of this case | 16-24 / 73-8 / 89-22 / 8 |
|  | **11b** | Discussion of the relevant medical literature | 16-29 / 7 |
|  | **11c** | The rationale for conclusions (including assessment of possible causes) | 23-29 / 8 |
|  | **11d** | The main “take-away” lessons of this case report | 23-29 / 8 |
| **Patient Perspective** | **12** | Did the patient share his or her perspective or experience? (Include when appropriate) | **Yes** |
| **Informed Consent** | **13** | Did the patient give informed consent? Please provide if requested | **Yes**  |
| **Additional Information** |  | Acknowledgement section; Competing Interests; IRB approval when required | **Yes** |